Totally implantable venous access ports (TIVAP) are widely applied in cancer patients, primarily those requiring long-term intravenous infusion. Given the absence of clinical practice guidelines designed specifically for the use of TIVAP in cancer patients, the National Cancer Center, the Professional Committee of Interventional Oncology of Chinese Anti-Cancer Association, the Professional Committee on Minimally Invasive Intervention of World Association of Chinese Oncology, the Professional Committee of Intervention of Beijing Association of Oncology, and cancer prevention and control institutions from various provinces and cities have jointly established a guideline compilation committee comprising multidisciplinary experts. Drawing upon the latest research findings, this guideline has been formulated. It comprehensively covers the clinical application indications, preoperative preparation, intraoperative procedures, postoperative care, usage and maintenance, removal techniques, complication management, and quality control indicators related to TIVAP use in cancer patients. The recommendations were graded using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to ensure that the TIVAP technology can be used to serve cancer patients with greater safety and efficiency in clinical practice, thereby enhancing overall medical quality and patient satisfaction.

In recent years, the treatment of malignant tumors has continually advanced, significantly extending the survival period of cancer patients. Tumors are increasingly present as chronic diseases over the long term, and the cardiovascular toxicity associated with cancer treatment has become increasingly prominent, severely affecting the effective treatment and survival of cancer patients. As a result, cardio-oncology has gained considerable attention as an emerging discipline. However, cardiovascular diseases in cancer patients often have an insidious onset, and early identification and treatment are frequently overlooked. Throughout the course of cancer treatment, it is crucial to reasonably apply cardiac biomarkers for risk stratification, early identification, and screening of cardiovascular diseases in patients, as well as to improve the early diagnosis and treatment levels of cardiovascular diseases in cancer patients. To this end, Cardio-Oncology Group, Chinese Society of Cardiology in conjunction with Cardiovascular Expert Committee, China Medical Doctor Association of Laboratory Medicine, organized experts in relevant fields to compile this consensus. It aims to provide a basis for clinicians to standardize the screening and management of cardiovascular toxicity related to cancer treatment through the reasonable application of cardiac biomarkers.

Cancer treatment-induced thrombocytopenia (CTIT) is a common adverse event during anti-tumor treatment, of which incidence is related to tumor classification, regimens, course of chemotherapy, etc. CTIT may result in a series of events including bleeding, dose intensity reduction, chemotherapy delay, and in severe cases, even the need for platelet transfusion, ultimately affecting the implementation of treatment plan, increasing the cost of treatment, reducing treatment effect and quality of life, and leading to a poor prognosis. The treatment of CTIT should first identify the cause, assess the risk of bleeding, and then adopt treatment strategies according to the cause and severity of CTIT. The main treatments of CTIT include platelet transfusion, application of various types of platelet-producing drugs, and measures to reduce the additional loss of platelets. Among them, platelet-producing drugs mainly refer to platelet-stimulating factors, including recombinant human thrombopoietin (rhTPO), recombinant human interleukin 11(rhIL-11), and thrombopoietin receptor agonists (TPO-RAs). In addition, traditional Chinese medicine also has some assistance in raising platelets. Pharmacological prophylaxis in high-risk patients may help reduce the incidence and severity of CTIT. This consensus aims to support Chinese oncologists in the diagnosis and treatment of CTIT in China, reduce the risk of bleeding and improve the quality of life of patients.